InBrain Pharma to Present Positive Results from Its DIVE-I Phase I/II Clinical Trial for Parkinson’s Disease at the Congress of Parkinson’s Disease and Movement Disorders from September 27 to October 1 in Philadelphia
September 25, 2024 09:00 ET
|
INBRAIN PHARMA
Lille, September 25, 2024 - InBrain Pharma, a biopharmaceutical company specialized in neurodegenerative diseases, will present the positive results of its Phase I/II DIVE-I clinical trial for...
InBrain Pharma announces the publication of an article on the pharmacokinetic and pharmacodynamic limitations of L-DOPA in the management of Parkinson's disease in the Journal of Parkinson's Disease
September 11, 2024 10:30 ET
|
INBRAIN PHARMA
InBrain Pharma announces the publication of an article on the pharmacokinetic and pharmacodynamic limitations of L-DOPA in the management of Parkinson's disease in the Journal of Parkinson's...